{"id":"https://openalex.org/W2184900890","doi":null,"title":"in the two low-dose groups in the Prot\u00e9g\u00e9 teplizumab study) proved ineff ective.","display_name":"in the two low-dose groups in the Prot\u00e9g\u00e9 teplizumab study) proved ineff ective.","publication_year":2011,"publication_date":"2011-01-01","ids":{"openalex":"https://openalex.org/W2184900890","mag":"2184900890"},"language":"en","primary_location":{"id":"mag:2184900890","doi":null,"is_oa":false,"landing_page_url":"https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(11)60980-X.pdf","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null},"volume":null,"type":"article","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5042889303","display_name":"Jean\u2010Fran\u00e7ois Bach","orcid":"https://orcid.org/0000-0002-1282-6067","observed_orcids":["https://orcid.org/0000-0002-1282-6067"]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Jean\u2010Fran\u00e7ois Bach","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-1282-6067","affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":["https://openalex.org/A5042889303"],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11171","display_name":"Diabetes and associated disorders","score":0.986299991607666,"subfield":{"id":"https://openalex.org/subfields/1311","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11171","display_name":"Diabetes and associated disorders","score":0.986299991607666,"subfield":{"id":"https://openalex.org/subfields/1311","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10560","display_name":"Diabetes Management and Research","score":0.002899999963119626,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10031","display_name":"T-cell and B-cell Immunology","score":0.0017000000225380063,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/teplizumab","display_name":"teplizumab","score":1.0},{"id":"https://openalex.org/keywords/type-1-diabetes","display_name":"type 1 diabetes","score":0.8069999814033508},{"id":"https://openalex.org/keywords/anti-cd3-therapy","display_name":"anti-CD3 therapy","score":0.5590000152587891},{"id":"https://openalex.org/keywords/hyperglycemia","display_name":"hyperglycemia","score":0.6309999823570251},{"id":"https://openalex.org/keywords/treatment-timing","display_name":"treatment timing","score":0.4690000116825104},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.6729999780654907},{"id":"https://openalex.org/keywords/cytokine-release-syndrome","display_name":"cytokine release syndrome","score":0.7210000157356262},{"id":"https://openalex.org/keywords/epstein-barr-virus-reactivation","display_name":"Epstein-Barr virus reactivation","score":0.9039999842643738},{"id":"https://openalex.org/keywords/clinical-trial-endpoints","display_name":"clinical trial endpoints","score":0.5099999904632568},{"id":"https://openalex.org/keywords/phase-3-trial-design","display_name":"phase 3 trial design","score":0.6290000081062317}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5774756073951721},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.48122715950012207},{"id":"https://openalex.org/C112758219","wikidata":"https://www.wikidata.org/wiki/Q16038819","display_name":"Duration (music)","level":2,"score":0.45726829767227173},{"id":"https://openalex.org/C2780850621","wikidata":"https://www.wikidata.org/wiki/Q3961647","display_name":"Cytokine release syndrome","level":5,"score":0.41223758459091187},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.3303908407688141},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.28896084427833557},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.2244846522808075},{"id":"https://openalex.org/C3008058167","wikidata":"https://www.wikidata.org/wiki/Q84263196","display_name":"Coronavirus disease 2019 (COVID-19)","level":4,"score":0.14920169115066528},{"id":"https://openalex.org/C142362112","wikidata":"https://www.wikidata.org/wiki/Q735","display_name":"Art","level":0,"score":0.0},{"id":"https://openalex.org/C124952713","wikidata":"https://www.wikidata.org/wiki/Q8242","display_name":"Literature","level":1,"score":0.0},{"id":"https://openalex.org/C524204448","wikidata":"https://www.wikidata.org/wiki/Q788926","display_name":"Infectious disease (medical specialty)","level":3,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"mag:2184900890","doi":null,"is_oa":false,"landing_page_url":"https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(11)60980-X.pdf","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":21,"referenced_works":["https://openalex.org/W1876338319","https://openalex.org/W1968956496","https://openalex.org/W1995013492","https://openalex.org/W2032218738","https://openalex.org/W2041637201","https://openalex.org/W2057043713","https://openalex.org/W2058256973","https://openalex.org/W2072632162","https://openalex.org/W2074463323","https://openalex.org/W2078578609","https://openalex.org/W2084274322","https://openalex.org/W2099574171","https://openalex.org/W2111457140","https://openalex.org/W2116969222","https://openalex.org/W2123201047","https://openalex.org/W2126228008","https://openalex.org/W2131428761","https://openalex.org/W2140213275","https://openalex.org/W2149513114","https://openalex.org/W2149567581","https://openalex.org/W2171429103"],"related_works":["https://openalex.org/W2123592823","https://openalex.org/W4390824429","https://openalex.org/W7124312872","https://openalex.org/W4245569074","https://openalex.org/W7134806472","https://openalex.org/W4411291026","https://openalex.org/W4388491157","https://openalex.org/W4410798788","https://openalex.org/W4241631808","https://openalex.org/W4362619946"],"abstract_inverted_index":{"12":[0],"Another":[1,204],"very":[2],"important":[3],"result":[4],"that":[5,63,148],"follows":[6],"from":[7,236],"the":[8,13,40,60,64,75,92,97,103,114,140,211,234],"data":[9,142],"in":[10,39,153,155],"Protege":[11,69],"is":[12,158,201,206],"good":[14,98],"tolerance":[15],"of":[16,21,31,50,68,96,125,166,213],"teplizumab,":[17],"with":[18,144,182,195],"few":[19,189],"signs":[20],"cytokine":[22],"release":[23],"syndrome":[24],"and":[25,112,180,227,230],"no":[26],"biological":[27],"or":[28,198],"clinical":[29],"evidence":[30],"Epstein-":[32],"Barr":[33],"virus":[34],"reactivation":[35],"(as":[36],"was":[37],"noted":[38],"phase":[41,87,117],"2":[42],"trial":[43,89],"using":[44],"otelixizumab":[45],"at":[46],"a":[47,85,131,177,188],"cumulative":[48],"dose":[49,104,115],"48":[51],"mg":[52],"9":[53],").":[54],"What":[55],"can":[56,113],"we":[57],"expect":[58],"for":[59],"future?":[61],"Given":[62],"encouraging":[65],"fi":[66,76],"ndings":[67],"are":[70,151],"based":[71],"on":[72],"post-hoc":[73],"analyses,":[74],"rst":[77],"essential":[78],"step":[79],"will":[80],"obviously":[81],"be":[82,105,118,174,185],"to":[83,108,122,129,209],"plan":[84],"new":[86],"3":[88],"guided":[90],"by":[91,216],"present":[93],"data\u2014in":[94],"view":[95],"safety":[99],"profi":[100],"le,":[101],"could":[102,184],"slightly":[106],"increased":[107],"improve":[109],"effi":[110],"cacy,":[111],"escalation":[116],"eliminated":[119],"not":[120],"only":[121],"decrease":[123],"duration":[124],"treatment":[126,157,181],"but":[127],"also":[128],"reach":[130],"therapeutic":[132],"antibody":[133],"concentration":[134],"as":[135,137,160,162,176,193,200],"soon":[136,161],"possible?":[138],"Indeed,":[139],"current":[141],"accord":[143],"previous":[145,237],"results":[146],"showing":[147],"best":[149,208],"responses":[150],"recorded":[152],"patients":[154],"whom":[156],"started":[159,186],"possible":[163],"after":[164,191],"diagnosis":[165],"hyperglycaemia.":[167],"10":[168],"Ideally,":[169],"type":[170],"1":[171],"diabetes":[172],"should":[173],"regarded":[175],"medical":[178],"emergency":[179],"teplizumab":[183],"within":[187],"days":[190],"diagnosis,":[192],"compared":[194],"several":[196],"weeks":[197],"months":[199],"done":[202],"now.":[203],"challenge":[205],"how":[207],"approach":[210],"choice":[212],"endpoints,":[214],"which":[215],"defi":[217],"nition":[218],"must":[219],"involve":[220],"discussion":[221],"between":[222],"academic":[223],"experts,":[224],"drug":[225],"developers,":[226],"regulatory":[228],"authorities,":[229],"take":[231],"into":[232],"consideration":[233],"experience":[235],"trials.":[238]},"counts_by_year":[],"updated_date":"2025-11-06T04:12:42.849631","created_date":"2016-06-24T00:00:00"}